Combined treatment regimen for severe acne vulgaris

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Treatment of acne vulgaris remains an actual task of practical medicine. Despite the fact that the participation of severe acne in the structure of the morbidity of acne vulgaris is relatively small, precisely they most often leave behind scars, are accompanied by a pronounced cosmetic defect and significantly reduce the patient’s quality of life. Systemic treatment with isotretinoin is the gold standard of management of such patients, but this type of treatment is often accompanied by an exacerbation reaction, which negatively affects the general condition of the patient and reduces the compliance of treatment.

AIM: To determine the effectiveness of the combined use of isotretinoin and a systemic corticosteroid in the treatment of severe forms of acne.

MATERIALS AND METHODS: We observed 27 patients (16 men and 11 women) with severe or very severe grade on the IGA scale. All patients received combination therapy with isotretinoin (Sotret) at a dose of 0.5 mg/kg/day (cumulative dose from 120 to 150 mg/kg) for 8 months and prednisolone 30 mg/day 7 days, followed by dose reduction within a month. The assessment of treatment efficacy was based on the IGA scale, indicators DIA, DLQI and counting the number of inflammatory and non-inflammatory elements.

RESULTS: During the 8 months of the study, 81.4% of patients achieved a 2-point reduction in the degree on the IGA scale (“clear” or “almost clear skin”). The DLQI index showed 74.9% improvement compared to the start of treatment. The average DIA values decreased by 72%. The reduction in the number of inflammatory and non-inflammatory elements showed a marked clinical improvement (91.4% for nodules and 98.3% for pustules). Exacerbations of acne were recorded in 18.5% of patients.

CONCLUSIONS: Combined systemic treatment with isotretinoin and prednisolone for severe acne decreases the number of exacerbations and reduces the duration of treatment.

Full Text

Restricted Access

About the authors

Larisa S. Kruglova

Central State Medical Academy of Department of Presidential Affairs

Email: kruglovals@mail.ru
ORCID iD: 0000-0002-5044-5265
SPIN-code: 1107-4372

MD, Dr. Sci. (Med.), Professor

Russian Federation, 19/1A Marshala Timoshenko street, 121359, Moscow

Natalia V. Gryazeva

Central State Medical Academy of Department of Presidential Affairs

Author for correspondence.
Email: tynrik@yandex.ru
ORCID iD: 0000-0003-3437-5233
SPIN-code: 1309-4668

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, 19/1A Marshala Timoshenko street, 121359, Moscow

Anait V. Tamrazova

Central State Medical Academy of Department of Presidential Affairs

Email: anaittamrazova@gmail.com
ORCID iD: 0000-0002-4672-697X
SPIN-code: 1563-1190
Russian Federation, 19/1A Marshala Timoshenko street, 121359, Moscow

References

  1. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651–663. doi: 10.1016/j.jaad.2006.08.048
  2. Seattle WI. GBD Compare. Seattle: University of Washington; 2013. Available from: https://vizhub.healthdata.org/gbd-compare/
  3. Clayton RW, Göbel K, Niessen CM, et al. Homeostasis of the sebaceous gland and mechanisms of acne pathogenesis. Br J Dermatol. 2019;181(4):677–690. doi: 10.1111/bjd.17981
  4. Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther. 2016;(7):13–25. doi: 10.2147/AHMT.S55832
  5. Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18(10):821–832. doi: 10.1111/j.1600-0625.2009.00890.x
  6. Heng AH, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020;10(1):5754. doi: 10.1038/s41598-020-62715-3
  7. Clinical guidelines: Acne vulgaris. Russian Sosiety of Dermatovenerologists and Cosmetologists; 2020. 33 p. (In Russ).
  8. Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther. 2016;(7):13–25. doi: 10.2147/AHMT.S55832
  9. Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3–12. doi: 10.1111/bjd.13462
  10. Drozhdina MB. Fulminant acne. Modern solution of the problem. Vestnik Dermatologii i Venerologii. 2019;95(4):79–86. (In Russ). doi: 10.25208/0042-4609-2019-95-4-79-86
  11. Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol. 1994;19(4):303–308. doi: 10.1111/j.1365-2230.1994.tb01200.x
  12. Holland DB, Jeremy AH, Roberts SG, et al. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. Br J Dermatol. 2004;150(1):72–81. doi: 10.1111/j.1365-2133.2004.05749.x
  13. Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: An international consensus from the global alliance to improve outcomes in acne. J Am Acad Dermatol. 2018;78(2 Suppl 1):S1–S23.e1. doi: 10.1016/j.jaad.2017.09.078
  14. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973.e33. doi: 10.1016/j.jaad.2015.12.037
  15. Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol. 2013;54(3):157–162. doi: 10.1111/j.1440-0960.2012.00947.x
  16. Kubanova AA, Araviyskaya ER, Sokolovsky EV, et al. Systemic treatment of severe forms of acne: experience of using isotretinoin in Russian Federation. Bulletin of Dermatology and Venereology. 2013;89(5):102–114. (In Russ). doi: 10.25208/vdv579
  17. Evaristo LS, Bagatin E. Use of oral isotretinoin to treat acne in the public system: a hospital-based retrospective cohort. Sao Paulo Med J. 2019;137(4):363–368. doi: 10.1590/1516-3180.2018.054405072019
  18. Bauer LB, Ornelas JN, Elston DM, Alikhan A. Isotretinoin: controversies, facts, and recommendations. Expert Rev Clin Pharmacol. 2016;9(11):1435–1442. doi: 10.1080/17512433.2016.1213629
  19. Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162–169. doi: 10.4161/derm.1.3.9364
  20. Strahan JE, Raimer S. Isotretinoin and the controversy of psychiatric adverse effects. Int J Dermatol. 2006;45(7):789–799. doi: 10.1111/j.1365-4632.2006.02660.x
  21. Lee SY, Jamal MM, Nguyen ET, et al. Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(2):210–216. doi: 10.1097/MEG.0000000000000496
  22. Chivot M. Retinoid therapy for acne. A comparative review. Am J Clin Dermatol. 2005;6(1):13–19. doi: 10.2165/00128071-200506010-00002
  23. Fox L, Csongradi C, Aucamp M, et al. Treatment modalities for acne. Molecules. 2016;21(8):1063. doi: 10.3390/molecules21081063
  24. Cuellar-Barboza AB, Cárdenas-de la Garza JA, Martínez-Moreno A, et al. Corticosteroid therapy in patients with acne. Dermatol Rev Mex. 2018;62(6):506–515.
  25. Borghi A, Mantovani L, Minghetti S, et al. Acute acne flare following isotretinoin administration: potential protective role of low starting dose. Dermatology. 2009;218(2):178–180. doi: 10.1159/000182270
  26. Grando LR, Leite OG, Cestari TF. Pseudo-acne fulminans associated with oral isotretinoin. An Bras Dermatol. 2014;89(4):657–659. doi: 10.1590/abd1806-4841.20143024
  27. Guidance for industry acne vulgaris: developing drugs for treatment [accessed 2021 Febr 10]. Available at: www.fda.gov/downloads/Drugs/Guidances/UCM071292.pdf
  28. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x
  29. Hermes B, Praetel C, Henz BM. Medium dose isotretinoin for the treatment of acne. J Eur Acad Dermatol Venereol. 1998;11(2):117–121.
  30. Pandey D, Agrawal S. Efficacy of Isotretinoin and antihistamine versus isotretinoin alone in the treatment of moderate to severe acne: a randomised control trial. Kathmandu Univ Med J (KUMJ). 2019;17(65):14–19.
  31. Demircay Z, Kus S, Sur H. Predictive factors for acne flare during isotretinoin treatment. Eur J Dermatol. 2008;18(4):452–456. doi: 10.1684/ejd.2008.0441
  32. Rasi A, Behrangi E, Rohaninasab M, Nahad ZM. Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne. Adv Biomed Res. 2014;(3):103. doi: 10.4103/2277-9175.129693

Supplementary files

Supplementary Files
Action
1. Fig. 1. Ratio between the severity of acne according to the Investigator’s Global Assessment scale (IGA).

Download (119KB)
Indexing metadata
2. Fig. 2. Dynamics of changes of the Dermatological index of quality of life (DQLI) during therapy.

Download (105KB)
Indexing metadata
3. Fig. 3. Dynamics of changes of the Dermatological index of acne (DIA) during therapy.

Download (130KB)
Indexing metadata
4. Fig. 4. Dynamics of changes in the amount of inflammatory and non-inflammatory elements during therapy.

Download (155KB)
Indexing metadata

Copyright (c) 2021 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 015912 от 28.03.1997 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies